Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER-Vaxx combinations in metastatic gastric/GEJ cancer
NCT05311176Phase 2Terminated
- Sponsor
- Imugene
- Start
- Aug 2022
- Primary completion
- Apr 2024
- Modality
- Peptides, Vaccines & Immunotherapeutics, Adoptive Cell Transfer
- Countries
- 2
01
Overview
A Phase 2 trial of HER-Vaxx in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Imugene. Started Aug 2022; status: terminated.
02
Drugs
HER-Vaxx
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05311176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05311176.